Longeveron Inc. (LGVN): Price and Financial Metrics

Longeveron Inc. (LGVN): $3.66

-0.37 (-9.18%)

POWR Rating

Component Grades













Add LGVN to Watchlist
Sign Up

Industry: Biotech



in industry


  • Growth is the dimension where LGVN ranks best; there it ranks ahead of 62.97% of US stocks.
  • LGVN's strongest trending metric is Sentiment; it's been moving down over the last 179 days.
  • LGVN's current lowest rank is in the Quality metric (where it is better than 4.18% of US stocks).

LGVN Stock Summary

  • LGVN's went public 1.8 years ago, making it older than merely 7.48% of listed US stocks we're tracking.
  • With a price/sales ratio of 64.66, LONGEVERON INC has a higher such ratio than 96.89% of stocks in our set.
  • Revenue growth over the past 12 months for LONGEVERON INC comes in at -42.46%, a number that bests just 4.49% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to LGVN, based on their financial statements, market capitalization, and price volatility, are PROF, CHPT, VLD, CODX, and MNTS.
  • To dig deeper into the stock's financial statements, go to LGVN's page on browse-edgar?action=getcompany&CIK=0001721484.

LGVN Valuation Summary

  • LGVN's EV/EBIT ratio is -4.3; this is 150% lower than that of the median Healthcare stock.
  • Over the past 22 months, LGVN's price/sales ratio has gone up 46.8.

Below are key valuation metrics over time for LGVN.

Stock Date P/S P/B P/E EV/EBIT
LGVN 2022-11-25 68.9 3.7 -4.9 -4.3
LGVN 2022-11-23 68.7 3.7 -4.9 -4.3
LGVN 2022-11-22 63.5 3.4 -4.5 -3.9
LGVN 2022-11-21 62.7 3.3 -4.5 -3.9
LGVN 2022-11-18 64.4 3.4 -4.6 -4.0
LGVN 2022-11-17 66.0 3.5 -4.7 -4.1

LGVN Stock Price Chart Interactive Chart >

Price chart for LGVN

LGVN Price/Volume Stats

Current price $3.66 52-week high $35.75
Prev. close $4.03 52-week low $3.15
Day low $3.64 Volume 87,100
Day high $4.04 Avg. volume 1,697,385
50-day MA $3.75 Dividend yield N/A
200-day MA $6.32 Market Cap 76.81M

Longeveron Inc. (LGVN) Company Bio

Longeveron LLC is a clinical stage biotechnology company that engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers in October 9, 2014 and is headquartered in Miami, FL.

LGVN Latest News Stream

Event/Time News Detail
Loading, please wait...

LGVN Latest Social Stream

Loading social stream, please wait...

View Full LGVN Social Stream

Latest LGVN News From Around the Web

Below are the latest news stories about LONGEVERON INC that investors may wish to consider to help them evaluate LGVN as an investment opportunity.

Longeveron (LGVN) Gets a Buy from Maxim Group

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Longeveron (LGVN - Research Report), with a price target of $14.00. The company's shares opened today at $4.09.According to TipRanks, Okunewitch is an analyst with an average return of -28.7% and a 20.69% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as TFF Pharmaceuticals, Gilead Sciences, and Kiora Pharmaceuticals.Currently, the analyst consensus on Longeveron is a Moderate Buy with an average price target of $14.00.See the top stocks recommended by analysts >>The company has a one-year high of $45.00 and a one-year low of $2.84.

Christine Brown on TipRanks | November 16, 2022

Longeveron Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

Longeveron ( NASDAQ:LGVN ) Third Quarter 2022 Results Key Financial Results Net loss: US$5.24m (loss widened by 8.0...

Yahoo | November 16, 2022

Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results

-- Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron’s Phase 2a trial for Alzheimer’s Disease -- -- Conference call scheduled for 8:30 a.m. ET today -- MIAMI, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for

Yahoo | November 14, 2022

LGVN: Making Exciting Progress

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) is a clinical stage biotech company that is using cutting edge cellular technology to treat a rare heart disease and the impacts of aging. Longeveron reported a 3Q 2022 loss of $0.25/per share, in line with the same quarter last year and within the range of expectations. More importantly, on a conference

Yahoo | November 14, 2022

Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’s Disease

MIAMI, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced the completion of enrollment in its Phase 2a trial of Lomecel-BTM in patients with mild Alzheimer’s Disease (AD). “We are pleased to have completed enrollment in our Phase 2a study of Lomecel-BTM for Alzheimer’s Disease. We look forward to building on our Phase 1b study, which met its

Yahoo | November 10, 2022

Read More 'LGVN' Stories Here

LGVN Price Returns

1-mo 1.10%
3-mo -24.38%
6-mo -58.08%
1-year -86.06%
3-year N/A
5-year N/A
YTD -69.68%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.746 seconds.